Navigation Links
Moffitt Cancer Center study validates activity of rare genetic variant in glioma

Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma.

The study, the first to confirm a rare susceptibility variant in glioma, appeared in a recent issue of the Journal of Medical Genetics, a journal published by the British Medical Association.

"Glioma is a poorly understood cancer with high morbidity and devastating outcomes," said study lead author Kathleen M. Egan, Sc.D., interim program leader of Cancer Epidemiology and vice chair of the Department of Cancer Epidemiology. "However, the discovery of the association of the TP53 genetic variant rs78378222 with glioma provides new insights into these tumors and offers better prospects for identifying people at risk."

According to the authors, their study "genotyped' the single nucleotide polymorphism (SNP, or "snip") rs78378222 in TP53, an important tumor suppressor gene. The researchers said the SNP disrupts the TP53 signal and, because of its activity, has been linked to a variety of cancers. This study linked the presence of the rare form of rs78378222 to deadly glioma.

The researchers conducted a large, clinic-based, case-control study of individuals age 18 and older with a recent glioma diagnosis. A total of 566 glioma cases and 603 controls were genotyped for the rs78378222 variant.

Study results reveal that the odds of developing glioma were increased 3.5 times among the rare variant allele carriers. However, when researchers examined the impact of rs78378222 on survival, they found an approximately 50 percent reduction in death rates for those who were variant allele carriers.

"That the variant increased survival chances was an unexpected finding," Egan said. "It is tempting to speculate that the presence of the risk allele could direct tumor development into a less aggressive path."

The researchers concluded that their study results "may shed light on the etiology and progression of these tumors."

In addition to researchers from Moffitt, researchers from The University of Alabama at Birmingham, Emory School of Medicine and Vanderbilt University participated in the study and co-authored the paper.


Contact: Patty Kim
H. Lee Moffitt Cancer Center & Research Institute

Related medicine news :

1. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
2. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
3. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
4. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
5. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
6. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
7. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
10. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
11. Moffitt researcher publishes book on nutritional management of cancer treatment effects
Post Your Comments:
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology: